“Throughout these first months of 2022, Orchard has realized early commercial launch momentum for Libmeldy as the first HSC gene therapy with ...
https://www.google.com/url?rct=j&sa=t&url=https://stockhouse.com/news/press-releases/2022/05/12/orchard-therapeutics-reports-first-quarter-2022-financial-results-and-highlights&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw175J3CJwMQfAJY29I_BIL-
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.